LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Kodu・Aktsiate loetelu・Guardant Health Inc

Guardant Health Inc

Suletud

SektorTervishoid

126.95 -2.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

125.2

Max

129.77

Põhinäitajad
By Trading Economics
Sissetulek	16M -112M
Müük	20M 302M
Aktsiakasum	-0.45
Kasumimarginaal	-37.152
Töötajad	2,490
EBITDA	18M -101M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+5.2% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	5B 17B
Eelmine avamishind	129.22
Eelmine sulgemishind	126.95

Uudiste sentiment

By Acuity

50%

154 / 344 Pingereas Healthcare

Guardant Health Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. juuni 2026, 23:22 UTC

Tulu

Suurimad hinnamuutused turgudel

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3. juuni 2026, 23:09 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3. juuni 2026, 20:51 UTC

Tulu

Costco Reports 15% Sales Growth in May

3. juuni 2026, 20:43 UTC

Tulu

Broadcom 2Q Revenue Climbs on AI Chip Demand

3. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3. juuni 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. juuni 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3. juuni 2026, 23:15 UTC

Market Talk

Tulu

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3. juuni 2026, 22:08 UTC

Kuumad aktsiad

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3. juuni 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3. juuni 2026, 21:18 UTC

Tulu

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3. juuni 2026, 21:15 UTC

Tulu

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3. juuni 2026, 21:13 UTC

Tulu

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3. juuni 2026, 21:13 UTC

Tulu

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3. juuni 2026, 21:12 UTC

Tulu

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3. juuni 2026, 21:09 UTC

Tulu

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3. juuni 2026, 21:03 UTC

Tulu

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. juuni 2026, 20:43 UTC

Tulu

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3. juuni 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3. juuni 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3. juuni 2026, 20:35 UTC

Tulu

Broadcom Stock Falls Despite Record Results -- Barrons.com

3. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3. juuni 2026, 20:17 UTC

Tulu

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3. juuni 2026, 20:17 UTC

Tulu

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Adj EPS $2.44 >AVGO

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q EPS $1.91 >AVGO

3. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Rev $22.19B >AVGO

Võrdlus sarnastega

Hinnamuutus

Guardant Health Inc Prognoos

Hinnasiht

By TipRanks

5.2% tõus

12 kuu keskmine prognoos

Keskmine 136.94 USD 5.2%

Kõrge 160 USD

Madal 120 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Guardant Health Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Guardant Health Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.